Show Preview: Biosensors for Medical Wearables

Innovations in Wearable Device Technology for Therapeutic Applications
October 23–24, 2023
Courtyard by Marriott, Boston, MA
www.biosensors-medical-wear.com

SAE Media Group’s 3rd Annual Biosensors for Medical Wearables Conference will be back for 2023 in Boston to bring together device developers, medtech, component manufacturers, and big pharma to share and discuss the exciting advances in the medical wearable technology landscape.

The wearable biosensors market has grown significantly in recent years leading to increasingly growing potential for medical applications and at home alternatives for patients. With growing applications and potential in remote patient monitoring, diagnosis, therapeutics and detection of disease, wearable sensors are attracting considerable interest due to their opportunities in better supporting patients, clinical outcomes, and decisions.

Furthermore, AI and connected technologies are furthering the potential opportunities of this industry. However, challenges including flexibility of wearable devices, the collection of clinical-grade data and advanced battery technologies still remain for the industry to overcome. This year’s conference looks to address these hot topics through case studies and industry insights.

This is a must attend event, giving you the chance to engage in the latest innovations that are accelerating the wearable biosensors industry. We hope to welcome you in October 2023!

LETTER FROM THE CHAIRS

As chairs of the conference, it is with great pleasure that we welcome you to SAE’s Biosensors for Medical Wearables Conference taking place in Boston on the 23rd and 24th of October 2023.

The conference will bring together expertise from individuals across the medical wearable technology field and offer a series of presentations that will address the latest innovations in the development of on-body sensors and their applications.

With growing applications and potential in remote patient monitoring, diagnosis, therapeutics and detection of disease, wearable sensors are attracting considerable interest due to their opportunities in better supporting patients, clinical outcomes, and decisions. AI and connected technologies are also furthering the potential opportunities of this industry, and such hot topics will be addressed through industry outlooks and case studies which will allow attendees to benchmark against developments and innovations in the field.

As the chairs of this conference, we look forward to welcoming you to this must-attend event in October!

Yours Sincerely,

Andreas Caduff,

Strategic Advisory Board, DiME

Lorelie Villarete,

Manager, Clinical Affairs, Lingo Sensing Technology Unlimited Company (an Abbott Company)

The Future of the Digital Therapeutics and Medical Wearables Market: Q&A with Tim Callahan, VP, Scientific Affairs, Philips Pharma Solutions, and with Janet Nikolovski, New Venture Lead, Johnson & Johnson

The digital therapeutics and medical wearables market has matured greatly over recent years. What key differences have you noticed in the last year regarding significant developments?

Tim Callahan: We are now understanding the regulatory guidance more and trying to conform clinical trials to meet the guidance and collect better data. Clinical trials, especially late phase, are looking to wearables as a viable alternative to traditional collection methods.

Janet Nikolovski: The COVID pandemic has accelerated the adoption of remote patient monitoring. We have also seen more clinical studies adopting digital technologies.

What do you see as the greatest challenge facing the industry at the moment?

TC: Standardization. Clinical trials are predicated on collecting data to meet safety and efficacy endpoints. These can be statistically driven. Unless we standardize the data collection method (including precision and standardized software), we might be in danger of missing these endpoints.

JN: One challenge is the need for generating robust clinical evidence to support the efficacy and safety of digital monitoring solutions and therapeutics and doing this inclusive of underrepresented populations typically addressed in clinical trials.

What current hot topic will you be addressing in your presentation, and what would you say makes it relevant to 2023?

TC: Using wearables in clinical trials and how the data can be analyzed (compared to traditional methods). This will include how AI will be important in the future.

JN: The use of smart phones and wearables in clinical trials can allow us to access broad, large populations, not be limited by need for clinical sites, reduce costs, and complexity. However, lack of sustained patient engagement and complete follow-up can be a significant challenge. Several remote digital health studies using mobile applications and wearable devices have been successful to retain high participation in short term, or with high touch. But long term, digital studies requiring engagement over years has proven challenging. We will share our design process for the Heartline Study, an app-based, large, siteless clinical trial lasting two years, comprised of an Apple Watch and a custom digital engagement program. The high rates of sustained, longitudinal engagement achieved in that study, and the insights we gained, we hope can inform the design of future trials.

How would you like to see the market develop in the future, and where do you think the biggest growth area will be in 2023?

TC: Wearables will fill a niche in clinical trials. We will need to start with later phase trials and then move the collection of data to earlier phases. However, we need to start with widespread surveys with these devices. This usually happens in postmarketing surveillance. Concurrently, we should be able to seed Phase 3 trials with remote data collection using wearables to collect more, real-life data.

JN: I’d like to see greater convergence of clinical and consumer devices that are easy to use but deliver on patient expectations and outcomes. While there are opportunities in each in each space separately, the biggest opportunity is to demonstrate outcomes that matter to payers, providers and ultimately patients/consumers.

And on a final note … Why do you feel it is important for the industry to join this year’s Biosensors for Medical Wearables conference?

TC: The industry is growing and changing rapidly. Keeping up with these changes, including benchmarking of your own projects, in crucial to stay current in this field.

JN: To hear the latest challenges and exciting opportunities in this industry and the broad ways different groups are addressing them.

---